HalcyGen works on IND

By Dylan Bushell-Embling
Friday, 18 July, 2008

Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.

The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.

It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.

According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.

Related News

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd